Bringing AI-driven protein-design tools to biologists everywhere

2026-04-17 · Source: MIT News - Artificial intelligence · Field: Science & Research — Life Sciences & Biology, Health & Medical Research, Mathematics & Computational Sciences · Depth: Advanced, medium

Summary

OpenProtein.AI, founded by Tristan Bepler PhD ’20 and former MIT professor Tim Lu PhD ’07, provides open-source models and a no-code platform for protein engineering. The company aims to democratize access to advanced AI tools for biologists, enabling them to design proteins, predict structure and function, and train models without extensive machine learning expertise. Their platform, featuring models like PoET and PoET-2, is utilized by pharmaceutical and biotech companies, including Boehringer Ingelheim, and is offered free to academic scientists. PoET-2, released last year, reportedly outperforms larger models with fewer computational resources and less experimental data. The initiative seeks to accelerate drug development and enhance the design of novel proteins with specific traits, extending to non-protein modalities.

Key takeaway

For AI Scientists and Biologists seeking to integrate advanced AI into protein engineering, OpenProtein.AI offers a critical solution. Its no-code platform and powerful foundation models, like PoET-2, enable rapid protein design and optimization, potentially shortening development cycles for therapeutics. You should explore this platform to enhance your research capabilities and contribute to an open ecosystem for AI in biology, ensuring broader access to cutting-edge tools.

Key insights

Democratizing AI-driven protein design tools empowers biologists to accelerate drug discovery and engineer novel proteins.

Principles

• AI accelerates drug development.
• No-code platforms broaden AI access.
• Open access fosters scientific progress.

Method

OpenProtein.AI's platform allows biologists to upload data, use protein language models like PoET, generate and optimize protein sequences in silico, and analyze results via an intuitive web interface or APIs.

In practice

• Design novel proteins with specific traits.
• Optimize protein sequences for therapeutics.
• Predict protein structure and function.

Topics

• OpenProtein.AI
• Protein Engineering
• AI-driven Drug Discovery
• Protein Language Models
• No-code AI Platform

Best for: Executive, AI Scientist, Research Scientist, Domain Expert, Director of AI/ML

Related on AIssential

• From discovery to design: in conversation with Ali Madani (Profluent) — AI-driven language models can design novel, functional proteins from scratch, accelerating biological evolution for therapeutic applications.
• ‘An AlphaFold 4’ – scientists marvel at DeepMind drug spin-off’s exclusive new AI — Isomorphic Labs' proprietary IsoDDE model significantly advances AI drug discovery, outperforming open-source alternatives in binding affinity prediction.
• 🗞️ Techie uses ChatGPT and AlphaFold to build DIY mRNA cancer vaccine, saves dog — AI tools empower individuals without specialized training to conduct complex scientific research and develop novel solutions.
• Designing Protein Binders Using the Generative Model Proteina-Complexa — Proteina-Complexa co-designs protein binders and enzymes using a latent flow-matching generative model with inference-time optimization.
• Why We're Not Close to AI Drugs Yet | Isomorphic Labs — Drug design comprises multiple distinct ML problems, not a single one, despite AlphaFold 2's protein structure prediction success.
• The scientist using AI to hunt for antibiotics just about everywhere — AI-driven peptide discovery from diverse biological sources offers a novel approach to combat antimicrobial resistance.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by MIT News - Artificial intelligence.